The OncoStent scaffold enables highly effective therapy after minimally invasive implantation. Special proteins bind and modify metastatic cancer cells before they can metastasize in the liver. Another therapeutic approach is based on the recruitment of immune and tumor cells in the scaffold in order to increase the effector: target ratio.
The OncoStent scaffold acts as a so-called “gatekeeper” for the liver aiming at sustained liver function to significantly improve the quality of life of the critical ill patient.
The in-vitro tests are carried out in a so-called Chandler loop system. This is an established test system that is used in accordance with ISO standard 10993-4 to determine the hemocompatibility of medical products (Wacker et al., 2020). The Chandler Loop serves as an upstream in-vitro safety and ranking bioassay.